U.S. Markets open in 7 hrs 28 mins

DexCom, Inc. (DXCM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
327.72+8.04 (+2.52%)
At close: 4:00PM EST
Sign in to post a message.
  • r
    Conference at 3pm EST...any news yet? It just hit the upward trend line on the 1yr weekly chart..normally bounces around 70.00 after it hits support..I bought dec 18 320 calls..let her rip! GLTA
  • R
    An Oramed pill to facilitate taking Insulin orally would expand the T2 market especially in China with ORMP China relationship. Another 200-600 million potential users? A huge DXCM opportunity developing just as we see the G7 coming in the quarters ahead.
  • R
    Ro S
    weird stock and weird price manipulation...
  • T
  • P
    Does this stock ever go up?
  • A
    I was in this for a day. Then realized it’s going to down trend for a while until it’s PE matches up with TMO’s
  • T
    Could some insiders know something we don't? If it continues to behave as the way it has been lately, it won't take long to go under $200.
  • r
    So ridiculously cheap here. The bears keep giving me more and more opportunities to load up on this. They may think they’ve made money now but they will lose it all soon. 400 is coming back then 500.
  • M
    If you’ve been buying these wild, senseless dips and ignoring the shorts and bots fueling this chat then you’re feeling good. Stay patient, ignore the noise.
  • R
    All eyes on December 8 analyst day meeting.
    JPMorgan analyst thinks one should take advantage of this sell off.
    . "With G7 on track, great margins, solid 40% volume growth, and record new patient adds in 3Q, we think the sell-off is excessive and would recommend buying here.
    The G7 US approval trial has already begun – we’ve confirmed this with management. Postings to
    clinicaltrials.gov don’t always precede the trial starting, and yes, the US approval trial has already started. We know there was significant speculation of a delay heading into earnings, so this is an important point."
  • M
    Mike Adams
    I sold my shares in October
    Reason- Abbie, novonordisc, Pfizer, & one other co have continuous release glucose
    ABV is approved thru insurance and 1/2 the price
    This is DXCM’s only business

    You decide
  • s
    Once I saw dxcm ad on TV, I realized the growth has slowed down. The growth rate is what drove the valuation this high
  • r
    Shorts may think they’ve made a killing on this latest dip, but it’s pocket change compared to what longs like me have made. Shorts should’ve covered already. 400 is coming back to a theater to near you and now is the time to take advantage and buy this generous dip.
  • D
    Any opinion on what will happen to stock price tomorrow after earnings announced
  • N
    All moving averages slopping down. When will DXCM recover?
  • B
    It’s official everyone: I’m bad luck. Literally every stock I buy goes down and doesn’t come back up. SIRI at 7, ZM at 555, DXCM at 395, and PTOB at 134. I must have offended my Lord God. Until I repent we will all suffer.
  • J
    Third Quarter 2020 Financial Highlights:

    Revenue grew 26% versus the same quarter of the prior year to $500.9 million
    U.S. revenue growth of 29% and international revenue growth of 17%
    GAAP operating income of $94.1 million or 18.8% of revenue, an increase of 470 basis points compared to the third quarter of 2019. Non-GAAP operating income* of $95.0 million or 19.0% of revenue, an increase of 410 basis points over the same quarter of the prior year
  • A
    I cant believe this #$%$ DXCM blows out the quarter on both top and bottom line, a few analyst reduce their price targets to like 450, and the stock tanks. talk about manipulation, the hedgies are trying to shake out the weak holders, using the spike in the virus to do so as well as the election. this should easily be trading at 450.00 after those earnings.
  • A
    WOW GREAT EARNINGS with Upward revisions to YE on all areas, great job DXCM!
  • j
    who would buy this again after it lost 100 in a matter of 2.5 weeks after great earnings